Gemphire Therapeutics (NASDAQ:GEMP) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday.
Other equities research analysts also recently issued reports about the company. Zacks Investment Research upgraded Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a report on Thursday, November 16th. Roth Capital restated a “buy” rating and set a $30.00 price objective on shares of Gemphire Therapeutics in a report on Friday, December 22nd. Piper Jaffray Companies restated an “overweight” rating and set a $22.00 price objective on shares of Gemphire Therapeutics in a report on Friday, October 27th. Canaccord Genuity restated a “buy” rating and set a $31.00 price objective on shares of Gemphire Therapeutics in a report on Monday, October 23rd. Finally, HC Wainwright lifted their price objective on Gemphire Therapeutics from $22.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, January 26th. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the stock. Gemphire Therapeutics has an average rating of “Hold” and a consensus target price of $23.17.
Gemphire Therapeutics (NASDAQ:GEMP) opened at $6.38 on Thursday. The company has a current ratio of 4.17, a quick ratio of 4.17 and a debt-to-equity ratio of 1.00. Gemphire Therapeutics has a 52-week low of $6.16 and a 52-week high of $21.59. The company has a market capitalization of $67.84 and a P/E ratio of -2.20.
A number of hedge funds have recently bought and sold shares of GEMP. Vanguard Group Inc. increased its holdings in Gemphire Therapeutics by 137.6% during the 2nd quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock worth $399,000 after purchasing an additional 17,892 shares during the last quarter. Advisory Services Network LLC bought a new stake in shares of Gemphire Therapeutics in the 2nd quarter valued at approximately $139,000. Northpointe Capital LLC increased its holdings in shares of Gemphire Therapeutics by 91.8% in the 3rd quarter. Northpointe Capital LLC now owns 520,292 shares of the company’s stock valued at $4,943,000 after acquiring an additional 249,077 shares during the last quarter. Comerica Bank bought a new stake in shares of Gemphire Therapeutics in the 3rd quarter valued at approximately $850,000. Finally, Cambridge Investment Research Advisors Inc. increased its holdings in shares of Gemphire Therapeutics by 4.5% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 159,964 shares of the company’s stock valued at $1,520,000 after acquiring an additional 6,900 shares during the last quarter. Institutional investors own 32.21% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/02/10/gemphire-therapeutics-gemp-stock-rating-lowered-by-valuengine.html.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.